MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$42,501K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Sales of marketable securities
Stock-based compensation
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Accretion of discount on marketa...
Prepaid expenses and other asset...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-57,327
-49,013
-50,216
-40,666
Depreciation
541
537
525
559
Stock-based compensation
9,362
8,715
9,875
8,085
Accretion of discount on marketable securities, net
809
1,013
1,483
2,056
Amortization of right-of-use asset
56
53
50
47
Prepaid expenses and other assets
579
-3,045
2,715
1,298
Accounts payable
781
1,446
-303
-2,132
Accrued compensation
2,898
-6,752
4,432
2,362
Accrued other expenses and other liabilities
2,811
635
1,436
548
Lease liability
-203
-196
-193
-189
Net cash used in operating activities
-42,469
-42,543
-38,592
-34,776
Purchases of marketable securities
53,085
110,152
74,285
66,999
Sales of marketable securities
22,800
3,966
15,932
51,452
Maturities of marketable securities
108,807
108,879
108,188
319,120
Purchases of property and equipment
32
260
73
183
Net cash provided by (used in) investing activities
78,490
2,433
49,762
35,716
Proceeds from issuance of common stock, net of offering costs
-
-
0
0
Exercise of stock options
2,294
12,173
3,650
1,659
Proceeds from employee stock purchase plan
793
-
325
0
Net cash provided by financing activities
3,087
12,173
3,975
1,659
Net change in cash and cash equivalents
39,108
-27,937
15,145
2,599
Cash and cash equivalents at beginning of period
33,211
61,148
46,003
41,666
Cash and cash equivalents at end of period
72,319
33,211
61,148
46,003
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of marketable
securities
$108,807K
(-52.51%↓ Y/Y)
Exercise of stock options
$2,294K
(-8.02%↓ Y/Y)
Proceeds from employee
stock purchase plan
$793K
(32.61%↑ Y/Y)
Sales of marketable
securities
$22,800K
(-41.01%↓ Y/Y)
Net cash provided by
(used in) investing...
$78,490K
(166.37%↑ Y/Y)
Net cash provided by
financing activities
$3,087K
(-98.38%↓ Y/Y)
Canceled cashflow
$53,117K
Net change in cash
and cash...
$39,108K
(2150.17%↑ Y/Y)
Canceled cashflow
$42,469K
Purchases of marketable
securities
$53,085K
(-86.25%↓ Y/Y)
Purchases of property and
equipment
$32K
(-65.96%↓ Y/Y)
Stock-based compensation
$9,362K
(-44.25%↓ Y/Y)
Accrued compensation
$2,898K
(165.57%↑ Y/Y)
Accrued other expenses
and other...
$2,811K
(317.40%↑ Y/Y)
Accounts payable
$781K
(-71.15%↓ Y/Y)
Depreciation
$541K
(-45.90%↓ Y/Y)
Amortization of right-of-use
asset
$56K
(-34.12%↓ Y/Y)
Net cash used in
operating activities
-$42,469K
(39.72%↑ Y/Y)
Canceled cashflow
$16,449K
Net loss
-$57,327K
(25.47%↑ Y/Y)
Accretion of discount on
marketable securities, net
$809K
(-80.39%↓ Y/Y)
Prepaid expenses and
other assets
$579K
(-85.34%↓ Y/Y)
Lease liability
-$203K
(44.54%↑ Y/Y)
Buy us a coffee
Edgewise Therapeutics, Inc. (EWTX)
Edgewise Therapeutics, Inc. (EWTX)